


Figure 1A




Figure 1B




Figure 1C




Figure 1D



5000 pfu
Survival rate (%)
Days post-infection
500 pfu
NI
medium
PAR1
Survival rate (%)
Days post-infection
50 pfu
Survival rate (%)
Days post-infection
10 pfu
Survival rate (%)
Days post-infection

Figure 2A



Survival rate (%)
100
90
80
70
60
50
40
30
20
10
0
Control
Agonist PAR-1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Days post-treatement
Weight (%)
111
109
107
105
103
101
99
97
95
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Days post-treatment

Figure 2B



50 pfu
50 pfu + agonist PAR1
Viral titer (Log10)
2,5
2,0
1,5
1,0
0,5
0,0
*
*
24H
48H
Time post-infection
500 pfu
500 pfu + agonist PAR1
Viral titer (Log10)
7,0
6,0
5,0
4,0
3,0
2,0
1,0
0,0
*
24H
48H
Time post-infection

Figure 2C




Figure 3 A




Figure 3B



50
50 pfu +SCH
Viral titer (Log10)
1,8
1,6
1,4
1,2
1,0
0,8
0,6
0,4
0,2
24H
48 H
Time post-infection
500 pfu
500 pfu + SCH
4,0
3,5
3,0
2,5
2,0
1,5
1,0
0,5
24H
48 H
Time post-infection

Figure 3C